Technology | Wearables | March 28, 2016

New Kardia Band for Apple Watch Delivers Medical-grade ECG Anywhere

AliveCor creates wearable medtech category and extends Kardia product line

Kardia Band, Alivecor

The Alivecor Kardia Band for the Apple Watch enables anyone to perform a medical-grade ECG anywhere.

AliveCor, Inc., the leader in FDA-cleared electrocardiogram (ECG) technology for mobile devices, announced today the introduction of the first medical-grade ECG band for the Apple Watch, Kardia Band (pending FDA (510)k clearance, expected availability late spring) along with a new app for smartphones (available now). The Kardia Band for Apple Watch, and new Kardia app, represent a significant breakthrough in proactive heart health by allowing people to discretely capture their ECG anytime, anywhere.

Users can record a single-lead ECG by simply touching Kardia Band’s integrated sensor that communicates with the Watch app, Kardia by AliveCor. The atrial fibrillation (AF) detector then uses Kardia’s automated analysis process (algorithm) to instantly detect the presence of AF in an ECG, the most common cardiac arrhythmia and a leading cause of stroke. Also included is the Normal Detector, which indicates whether your heart rate and rhythm are normal, and the unreadable detector, which tells you when to retake an ECG so physicians receive only the highest quality recordings.

Users can also record voice memos on their Apple Watch to accompany each ECG that give doctors and caregivers a clearer picture of what was happening at the time of the recording — describing symptoms such as palpitations or external factors like caffeine intake. Kardia also integrates seamlessly with Apple’s Health app to include ECG data with steps and calorie intake to provide richer, personal analysis over time.

“Kardia Band for Apple Watch represents both the future of proactive heart health and the introduction of the Wearable MedTech category,” said Vic Gundotra, chief executive officer of AliveCor. “These combined technologies give us the ability to deliver personal reports that provide analysis, insights and actionable advice for the patient and their doctor.”

“The personal, discrete Kardia Band is a perfect fit for Apple Watch. It allows patients to easily measure and record their heart rhythm in real time. This can provide patients with a sense of control—which is vitally important to successful patient engagement in the treatment of chronic disease,” said Kevin R. Campbell, M.D., FACC, North Carolina Heart and Vascular UNC Healthcare, clinical cardiac electrophysiology assistant professor, UNC Department of Medicine, Division of Cardiology, and President, K-Roc Consulting, LLC.

Kardia Band is designed for anyone who wants to learn more about their health in addition to people with AF, and doctors who want to bring the latest in proactive heart health technology to their patients and practices. Kardia Band provides caregivers the opportunity to take a more active role in helping their loved one engage in their own care. The Kardia Band is pending 510k clearance and is not currently for sale in the United States.

AliveCor has re-introduced its first device, the AliveCor Mobile ECG, under the new Kardia brand name as Kardia Mobile. This change establishes a family of products and makes the name Kardia synonymous with proactive heart health. Currently, Kardia Mobile works with iPhone, iPad and iPod touch, and most Android OS. The new Kardia app is available now for download for iOS and Android users.

For more information: alivecor.com

 

Reference:

1. Based on the number of published clinical studies using Kardia Mobile compared to other smartphone-based EKG devices.

Related Content

Some of the top technology news from ACC 2021. Top left, the LAAOS III trial showed benefit when surgeons seal off the LAA during other open heart procedures. Bottom left, the ReCor Paradise renal denervation system helped lower blood pressure in patients who did not respond to medication. Top right, for patients with both heart failure and AFib it makes no differences is therapy is focused on controlling the heart rhythm or heart rate. Bottom right, the FLOWER-MI trial found no benefit to FFR-guided PCI.

Some of the top technology news from ACC 2021. Top left, the LAAOS III trial showed benefit when surgeons seal off the LAA during other open heart procedures. Bottom left, the ReCor Paradise renal denervation system helped lower blood pressure in patients who did not respond to medication. Top right, for patients with both heart failure and AFib it makes no difference if therapy is focused on controlling the heart rhythm or heart rate. Bottom right, the FLOWER-MI trial found no benefit to FFR-guided PCI in STEMI with multi-vessel disease.

Feature | ACC | June 08, 2021 | By Dave Fornell, Editor
Here are the top 10 takeaways from the late-breaking studies on cardiovascular technologies presented at the 2021 ...
AMERICAN COLLEGE OF CARDIOLOGY (ACC) Late-breaking clinical trial study presentations at ACC.21. @ACC21 @ACC2021
Feature | ACC | May 18, 2021 | Dave Fornell, Editor
The latest cardiology practice-changing scientific breakthrough, late-breaking study presentations have been announce
To help monitor the health of ACC 2021 in-person attendees for signs of COVID infection, the meeting will use BioIntelliSense's wearable BioButton continuous wireless temperature and vital signs monitoring. The wearable monitor is the size of a coin and is disposable.

To help monitor the health of ACC 2021 in-person attendees for signs of COVID infection, the meeting will use BioIntelliSense's wearable BioButton continuous wireless temperature and vital signs monitoring. The wearable monitor is the size of a coin and is disposable.

News | ACC | February 09, 2021 | By Dave Fornell, Editor
UPDATE Feb 22, 2021 — ...
The American College of Cardiology (ACC) released a list of the latest practice-changing presentations at the ACC.20 annual meeting March 28-30, 2020, in Chicago. This includes five late-breaking clinical trial (LBCT) sessions and three featured clinical research sessions. There also are two LBCT deep-dive sessions where the experts will break down the hottest trials and attendees can find out what the impact might be on the practice of cardiology and patients.
Feature | ACC | April 09, 2020 | Dave Fornell, Editor
Here is the list of American College of Cardiology (ACC) practice-
ACC Cancels 2020 Conference Amid Coronavirus Concerns. #COVID19 #coronavirus #2019nCoV
Feature | ACC | March 09, 2020 | Dave Fornell, Editor
March 9, 2020 — Less than week after the American College of Cardiolog...
American College of Cardiology Names Douglas Drachman Next Annual Scientific Session Vice Chair

Image courtesy of Massachusetts General Hospital

News | ACC | October 08, 2019
Douglas Drachman, M.D., FACC, has been selected as the next vice chair of the American College of Cardiology’s (ACC)...
SyncVision iFR Co-registration from Philips Healthcare maps pressure readings onto angiogram. Results from an international study presented at ACC 2019 indicates pressure readings obtained using iFR (instantaneous wave-free ratio, also referred to as instant wave-free ratio or instant flow reserve) in coronary arteries may localize stenoses that remain after interventions. FFR in the cath lab.

SyncVision iFR Co-registration from Philips Healthcare maps pressure readings onto angiogram. Results from an international study presented at ACC 2019 indicates pressure readings obtained using iFR (instantaneous wave-free ratio, also referred to as instant wave-free ratio or instant flow reserve) in coronary arteries may localize stenoses that remain after interventions.

Feature | ACC | March 27, 2019 | Greg Freiherr, Contributing Editor
The fingerprints of value-added medicine were all over products and works-in-progress on the exhibit floor of the a

The opening late-breaking trial at ACC 2019 is the Apple Heart Study, a large-scale, app-based study to identify atrial fibrillation using a smartwatch. Earlier, smaller trials showed this approach might be used in a population health application to proactively identify AFib patients earlier.

Feature | ACC | March 19, 2019
The American College of Cardiology (ACC) released a list of the late
A patient who received HeartMate III LVAD system at ACC.18. The HeartMate 3 was the topic of of the the key late-breaking trials at #ACC18

A patient who received the HeartMate III LVAD system showing off his external battery pack. He served as a patient ambassador in the Abbott booth at ACC.18. The HeartMate III, with its magnetic levitated pump, showed a big reduction in clotting over previous LVADs in a key late-breaking trial at this year's conference.

Feature | ACC | March 27, 2018 | Dave Fornell
There were several notable presentations of new data on cardiovascular technologies at the recent 2018 American Colle